US4952581A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
Assignee: Columbia University
•
Filing: 1988-12-30
•
Granted: 1990-08-28
•
Expires: 2008-12-30
Abstract
Abstract This invention provides a method for treating ocular hypertension or glaucoma in a subject's eye. The method comprises contacting the surface of the eye with an effective intraocular pressure reducing amount of a mixture of an adrenergic blocking agent and a prostaglandin or prostaglandin derivative in an ophthalmically compatible carrier, so as to reduce the intraocular pressure of the eye and maintain such reduced intraocular pressure. This invention also provides a composition for topical treatment of ocular hypertension or glaucoma in the eye of a subject. The composition comprises an effective intraocular pressure reducing amount of a mixture of an adrenergic block agent and a prostaglandin or prostaglandin derivative in an ophthalmically compatible carrier.
Inventors
- 👤 Laszlo Z. Bito
- 👤 Johan W. Stjernschantz
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 01:01
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/557
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
98 words
A method for treating ocular hypertension or glaucoma in a subject's eye which comprises contacting the surface of the eye with a composition comprising a beta-adrenergic blocking agent and an ester of prostaglandin F 2 α or a derivative of an ester of prostaglandin F 2 α in an ophthalmically compatible carrier, the amounts in the mixture being between about 5 μg and about 500 μg and between about 0.01 μg and about 1000 μg, respectively, and being such as to be effective so as to reduce the intraocular pressure of the eye and maintain such reduced pressure.
Claim 2
Independent Claim
98 words
A method for treating ocular hypertension or glaucoma in a subject's eye which comprises contacting the surface of the eye with a composition comprising a beta-adrenergic blocking agent and an ester of prostaglandin F 2 α or a derivative of an ester of prostaglandin F 2 α in an ophthalmically compatible carrier, the amounts in the mixture being between about 5 μg and about 500 μg and between about 0.01 μg and about 1000 μg, respectively, and being such as to be effective so as to reduce the intraocular pressure of the eye and maintain such reduced pressure.
Claim 3
Dependent Claim
13 words
The method of claim 1, wherein the beta-adrenergic blocking agent is timolol maleate.
Claim 4
Dependent Claim
13 words
The method of claim 1, wherein the beta-adrenergic blocking agent is betaxolol hydrochloride.
Claim 5
Dependent Claim
13 words
The method of claim 1, wherein the beta-adrenergic blocking agent is levobunolol hydrochloride.
Claim 6
Dependent Claim
17 words
The method of claim 1, wherein the PGF 2 α derivative is PGF 2 α -1-isopropyl ester.
Claim 7
Dependent Claim
34 words
A method of claim 1, wherein the prostaglandin F 2 α or derivative of prostaglandin F 2 α is present in the mixture in an amount between about 0.1 μg and about 500 μg.
Claim 8
Dependent Claim
14 words
A method of claim 1, wherein the ophthalmically compatible carrier comprises an aqueous solution.
Claim 9
Dependent Claim
35 words
A method of claim 7, wherein the aqueous solution is a saline solution containing an ophthalmically compatible preservative, a surfactant, and an agent, such as a soluble polymer, to increase the viscosity of the solution.
Claim 10
Dependent Claim
15 words
A method of claim 1, wherein the mixture is dissolved in the ophthalmically compatible carrier.
Claim 11
Dependent Claim
11 words
A method of claim 1, wherein the contacting is effected periodically.
Claim 12
Dependent Claim
14 words
A method of claim 10, wherein the periodic contacting is effected at least daily.
Claim 13
Dependent Claim
11 words
A method of claim 1, wherein the subject is a primate.
Claim 14
Dependent Claim
88 words
A composition for the topical treatment of ocular hypertension or glaucoma comprising a mixture of a beta-adrenergic blocking agent and an ester of prostaglandin F 2 α or a derivative of an ester of prostaglandin F 2 α in an ophthalmically compatible carrier and the amounts in the mixture being between 5 μg and about 500 μg and between about 0.01 μg and about 1000 μg, respectively, being such as to be effective so as to reduce the intraocular pressure of the eye and maintain such reduced pressure.
Claim 15
Dependent Claim
88 words
A composition for the topical treatment of ocular hypertension or glaucoma comprising a mixture of a beta-adrenergic blocking agent and an ester of prostaglandin F 2 α or a derivative of an ester of prostaglandin F 2 α in an ophthalmically compatible carrier and the amounts in the mixture being between 5 μg and about 500 μg and between about 0.01 μg and about 1000 μg, respectively, being such as to be effective so as to reduce the intraocular pressure of the eye and maintain such reduced pressure.
Claim 16
Dependent Claim
13 words
A composition of claim 13, wherein the beta-adrenergic blocking agent is timolol maleate.
Claim 17
Dependent Claim
13 words
A composition of claim 13, wherein the beta-adrenergic blocking agent is betaxolol hydrochloride.
Claim 18
Dependent Claim
13 words
A composition of claim 13, wherein the beta-adrenergic blocking agent is levobunolol hydrochloride.
Claim 19
Dependent Claim
17 words
A composition of claim 13, wherein the PGF 2 α derivative is PGF 2 α`- 1-isopropyl ester.
Claim 20
Dependent Claim
27 words
A composition of claim 13, wherein the prostaglandin or prostaglandin derivative is present in the mixture in an amount between about 0.1 μg and about 50 μg.
Claim 21
Dependent Claim
14 words
A composition of claim 13, wherein the ophthalmically compatible carrier comprises an aqueous solution.
Claim 22
Dependent Claim
35 words
A composition of claim 19, wherein the aqueous solution is a saline solution containing an ophthalmically compatible preservative, a surfactant, and an agent, such as a soluble polymer, to increase the viscosity of the solution.
Claim 23
Dependent Claim
15 words
A composition of claim 13, wherein the mixture is dissolved in the ophthalmically compatible carrier.
Claim 24
Independent Claim
65 words
A method for treating ocular hypertension or glaucoma in a primate subject's eye which comprises contacting the surface of the eye with a composition comprising an effective intraocular pressure reducing amount of a mixture of levobunolol hydrochloride and PGF 2 α`- 1-isopropyl ester dissolved in an ophthalmically compatible carrier, so as to reduce the intraocular pressure of the eye and maintain such reduced intraocular pressure.
Claim 25
Independent Claim
65 words
A method for treating ocular hypertension or glaucoma in a primate subject's eye which comprises contacting the surface of the eye with a composition comprising an effective intraocular pressure reducing amount of a mixture of levobunolol hydrochloride and PGF 2 α`- 1-isopropyl ester dissolved in an ophthalmically compatible carrier, so as to reduce the intraocular pressure of the eye and maintain such reduced intraocular pressure.
Claim 26
Dependent Claim
36 words
A composition for the topical treatment of ocular hypertension or glaucoma comprising an effective intraocular pressure reducing amount of a mixture of levobunolol hydrochloride and PGF 2 α`- 1-isopropyl ester dissolved in an ophthalmically compatible carrier.
Claim 27
Dependent Claim
36 words
A composition for the topical treatment of ocular hypertension or glaucoma comprising an effective intraocular pressure reducing amount of a mixture of levobunolol hydrochloride and PGF 2 α`- 1-isopropyl ester dissolved in an ophthalmically compatible carrier.
References Cited (Backward Citations)
US4599353A
Cited
US4474751A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-08-27 | 1994-02-26 | 1994-08-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-08-27 | 1998-02-26 | 1998-08-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-08-27 | 2002-02-26 | 2002-08-28 | $7700.00 | Window Closed / Lapsed |